+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dendritic Cell Cancer Vaccine Market - Global Forecast to 2030- Product Image
Dendritic Cell Cancer Vaccine Market - Global Forecast to 2030- Product Image
Sale

Dendritic Cell Cancer Vaccine Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967966
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dendritic Cell Cancer Vaccine Market grew from USD 392.59 million in 2024 to USD 444.97 million in 2025. It is expected to continue growing at a CAGR of 13.23%, reaching USD 827.59 million by 2030.

The field of dendritic cell cancer vaccines represents a pioneering frontier in oncology, harnessing the body’s own antigen-presenting cells to mount targeted immune responses against malignant cells. By isolating and activating dendritic cells ex vivo, researchers can introduce tumor-specific antigens that educate the immune system to recognize and eliminate cancerous tissue. This personalized immunotherapy approach promises enhanced safety profiles and reduced off-target effects compared to traditional chemotherapies.

Over the past decade, technological breakthroughs in cell culture, antigen identification and delivery methods have accelerated clinical pipelines. Collaborations between academic institutions, biotechnology firms and contract manufacturing organizations have fostered an ecosystem ripe for innovation. At the same time, challenges such as scalable manufacturing, batch consistency and regulatory harmonization continue to shape development strategies.

This executive summary explores the transformative shifts redefining the dendritic cell vaccine landscape, examines the cumulative impact of new U.S. tariffs on production and supply chains, delves into segmentation and regional insights, profiles leading industry players, and outlines actionable recommendations for leaders seeking to navigate this rapidly evolving market. By distilling key trends and strategic imperatives, we aim to equip decision-makers with the clarity needed to advance next-generation immunotherapies.

Transformative Shifts Shaping the Dendritic Cell Vaccine Landscape

Recent years have witnessed a paradigm shift in dendritic cell cancer vaccine development, driven by advances in antigen discovery, cell sourcing and bioengineering techniques. First, high-throughput neoantigen sequencing platforms have enabled the rapid selection of tumor-specific peptides, ushering in a new era of personalized vaccine constructs. Simultaneously, next-generation manufacturing innovations-such as microfluidic cell sorting and closed-system bioreactors-have improved yield, viability and consistency while reducing contamination risks.

Moreover, the transition from monotherapy toward combination regimens pairing dendritic cell vaccines with checkpoint inhibitors or adoptive T-cell therapies has unlocked synergistic potential, enhancing both response rates and durability. Translational research powered by artificial intelligence now accelerates predictive modeling of antigen-immune interactions, optimizing vaccine design before clinical deployment.

Regulatory agencies are responding to these technological strides by streamlining pathways for advanced therapy medicinal products, creating conditional approval frameworks that reward early demonstration of safety and immunogenicity. Cross-sector partnerships between biopharma, academia and contract research organizations have further propelled innovation, establishing proof-of-concept studies and forging standardized protocols that de-risk large-scale trials. Together, these forces are reshaping the competitive landscape and elevating dendritic cell vaccines from experimental therapies to viable commercial candidates.

Assessing the 2025 U.S. Tariff Impact on Vaccine Production

In 2025, newly implemented U.S. tariffs targeting imported cytokines, culture media components and specialized laboratory equipment have introduced notable cost pressures across the dendritic cell vaccine value chain. Manufacturers reliant on overseas suppliers now face elevated raw material expenses, which in turn drive R&D budgets to absorb incremental surcharges or identify alternative domestic sources. These shifts have amplified the importance of strategic supply chain mapping and onshore production capabilities.

Furthermore, tariff-induced delays in reagent shipments have compelled biotechnology firms to reassess inventory management practices and negotiate long-term agreements with multiple vendors to mitigate single-source dependencies. Consequently, process development timelines have been extended in some cases, necessitating proactive contingency planning to maintain clinical trial milestones.

Government incentives aimed at bolstering domestic biomanufacturing capacity are emerging in response to these challenges. Tax credits for capital investments in cell therapy facilities, coupled with grants for workforce training, are beginning to offset the cost burdens imposed by tariffs. Early adopters of reshoring strategies report gains in supply chain resilience and lead time reduction, underscoring the potential to transform a tariff-driven risk into a competitive advantage through vertical integration and strategic partnerships.

Key Segmentation Insights for Strategic Prioritization

A granular understanding of market composition is essential for effective resource allocation. By segmenting the field according to product type, fusion hybrid dendritic cell vaccines, protein antigen dendritic cell vaccines and pure dendritic cell vaccines each exhibit distinct manufacturing complexities and clinical profiles. When analyzed by application, the market bifurcates into hematological and solid tumor indications: leukemia and lymphoma-subdivided into Hodgkin and non-Hodgkin lymphoma-contrast with solid tumors such as breast cancer, colorectal cancer (further split into colon and rectal cancer), lung cancer and prostate cancer.

End-user dynamics reveal three primary channels: specialized cancer treatment centers, general hospitals and academic research institutes, each bringing unique procurement cycles and regulatory expectations. The source of dendritic cells also informs development strategies, differentiating allogeneic approaches from autologous methods that leverage patient-derived cells. Clinical trial activity spans from Phase I through Phase IV studies, reflecting a spectrum of early-stage safety evaluations to long-term post-marketing surveillance.

Administration routes range across intraperitoneal, intratumoral and intravenous delivery, influencing both patient experience and logistical requirements. Patient profiles differ by age group-adult, geriatric and pediatric-affecting dosing regimens and safety monitoring. Cutting-edge development technologies contrast peptide-loaded techniques with RNA-transfected platforms, each offering distinct antigen presentation efficiencies. Finally, mechanisms of action separate vaccines designed for direct tumor attack from those focused on broader immune system modulation. Together, these segmentation lenses guide strategic prioritization, illuminating high-value niches where clinical demand and technical feasibility align most favorably.

Key Regional Insights Driving Market Access Strategies

Regional considerations play a pivotal role in shaping market access and adoption trajectories. In the Americas, the United States leads with robust regulatory support for advanced cellular therapies and a well-established network of contract manufacturing organizations. Canada complements this with publicly funded clinical programs and strong academic-industry collaborations, creating a vibrant transborder ecosystem for vaccine development.

In Europe, Middle East & Africa, European Union member states benefit from centralized approval pathways and harmonized pharmacovigilance frameworks, while preclinical research hubs in the United Kingdom, Germany and Switzerland continue to drive innovation. In the Middle East, government-sponsored biotech initiatives are accelerating infrastructure development, and select African nations are investing in capacity building to support early-phase trials under emerging regulatory jurisdictions.

Asia-Pacific presents both high growth potential and diverse challenges. China’s large patient population and fast-track approval policies have catalyzed a surge in domestic dendritic cell vaccine programs, while Japan’s stringent regulation ensures rigorous safety standards. India and Australia round out the region with growing clinical pipelines and increasing partnerships between local biotech firms and multinational corporations. Understanding these regional nuances is vital for tailoring regulatory strategies and forging meaningful partnerships across jurisdictions.

Key Company Profiles Illuminating Competitive Differentiators

Leading companies are carving differentiated paths through strategic alliances, proprietary technology platforms and targeted clinical focuses. Aduro Biotech leverages its oncolytic virus expertise to enhance dendritic cell activation, while APAC Biotech capitalizes on regional manufacturing hubs to drive cost-effective production in Asia. Argos Therapeutics emphasizes personalized neoantigen workflows, integrating genomic sequencing with custom vaccine formulation.

Batavia Biosciences B.V. specializes in large-scale GMP cell culture and downstream processing, offering flexible solutions that address both autologous and allogeneic workflows. Creative Biolabs provides contract research services spanning antigen discovery to phase I bridging studies, enabling smaller developers to accelerate proof-of-concept. Dendreon Pharmaceuticals, renowned for its Provenge platform, brings decades of experience in commercialization and reimbursement strategies.

GSK PLC incorporates dendritic cell modalities into its expansive immuno-oncology raft, while ImmunoCellular Therapeutics pursues combination regimens targeting brain and solid tumors. JW CreaGene emerges as a regional innovator in China, focusing on intratumoral delivery systems. Northwest Biotherapeutics and Northwest Biotherapeutics, Inc. concentrate on central nervous system indications with their DCVAC portfolio. Nouscom explores virus-primed dendritic cell vaccines that harness onco-viral synergy. By benchmarking these players’ unique competencies, organizations can identify collaboration opportunities and competitive differentiators.

Actionable Recommendations for Industry Leaders

To capitalize on the momentum within dendritic cell vaccines, industry leaders should adopt a multifaceted strategic framework:

Leverage strategic partnerships with academic centers and contract manufacturing organizations to de-risk early-stage development and accelerate process validation. This collaborative approach can streamline access to specialized equipment and regulatory expertise.

Invest in modular, closed-system manufacturing platforms that accommodate both autologous and allogeneic workflows. Flexibility in production lines enables rapid pivoting between pipeline candidates, reducing capital intensity and improving scalability.

Pursue combination therapy trials that pair dendritic cell vaccines with immune checkpoint inhibitors or oncolytic agents. Early alignment with regulatory bodies on combination trial design can yield faster pathways to conditional approvals.

Expand geographic reach by establishing regional centers of excellence. Target markets such as China and select Middle Eastern countries offer expedited approval frameworks and sizeable patient populations, accelerating enrollment and data generation.

Prioritize advanced analytics and machine learning for neoantigen prediction and patient stratification. Data-driven insights enhance clinical trial design, improving both response rates and cost efficiency by focusing on high-probability responders.

Conclusion: Navigating the Future of Dendritic Cell Vaccines

The evolution of dendritic cell cancer vaccines reflects a dynamic interplay between scientific innovation, regulatory adaptation and strategic collaboration. As the field matures, organizations that integrate robust manufacturing capabilities with targeted clinical development and proactive supply chain resilience will secure a competitive advantage. Embracing modular production systems, forging cross-sector partnerships and harnessing advanced analytics will be critical to overcoming cost and timeline pressures.

By aligning segmentation priorities with regional regulatory landscapes and forming alliances that leverage complementary strengths, stakeholders can navigate tariff-induced challenges and unlock new value drivers. Moreover, focusing on patient-centric trial designs and sustainable operating models will foster long-term adoption and reimbursement success. This comprehensive perspective underscores the transformative potential of dendritic cell vaccines to redefine cancer treatment paradigms.

Market Segmentation & Coverage

This research report categorizes the Dendritic Cell Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Fusion Hybrid Dendritic Cell Vaccines
  • Protein Antigen Dendritic Cell Vaccines
  • Pure Dendritic Cell Vaccines
  • Cancers of the Blood
    • Leukemia
    • Lymphoma
      • Hodgkin Lymphoma
      • Non-Hodgkin Lymphoma
  • Solid Tumors
    • Breast Cancer
    • Colorectal Cancer
      • Colon Cancer
      • Rectal Cancer
    • Lung Cancer
    • Prostate Cancer
  • Cancer Treatment Centers
  • Hospitals
  • Research Institutes
  • Allogeneic Dendritic Cells
  • Autologous Dendritic Cells
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Intraperitoneal
  • Intratumoral
  • Intravenous
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients
  • Peptide-Loaded Dendritic Cells
  • RNA-Transfected Dendritic Cells
  • Direct Tumor Attack
  • Immune System Modulation

This research report categorizes the Dendritic Cell Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dendritic Cell Cancer Vaccine Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Aduro Biotech
  • APAC Biotech
  • Argos Therapeutics
  • Batavia Biosciences B.V.
  • Creative Biolabs
  • Dendreon Pharmaceuticals
  • GSK PLC
  • ImmunoCellular Therapeutics
  • JW CreaGene
  • Northwest Biotherapeutics
  • Northwest Biotherapeutics, Inc.
  • Nouscom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dendritic Cell Cancer Vaccine Market, by Product Type
8.1. Introduction
8.2. Fusion Hybrid Dendritic Cell Vaccines
8.3. Protein Antigen Dendritic Cell Vaccines
8.4. Pure Dendritic Cell Vaccines
9. Dendritic Cell Cancer Vaccine Market, by Application
9.1. Introduction
9.2. Cancers of the Blood
9.2.1. Leukemia
9.2.2. Lymphoma
9.2.2.1. Hodgkin Lymphoma
9.2.2.2. Non-Hodgkin Lymphoma
9.3. Solid Tumors
9.3.1. Breast Cancer
9.3.2. Colorectal Cancer
9.3.2.1. Colon Cancer
9.3.2.2. Rectal Cancer
9.3.3. Lung Cancer
9.3.4. Prostate Cancer
10. Dendritic Cell Cancer Vaccine Market, by End-User
10.1. Introduction
10.2. Cancer Treatment Centers
10.3. Hospitals
10.4. Research Institutes
11. Dendritic Cell Cancer Vaccine Market, by Source of Dendritic Cells
11.1. Introduction
11.2. Allogeneic Dendritic Cells
11.3. Autologous Dendritic Cells
12. Dendritic Cell Cancer Vaccine Market, by Clinical Trial Phases
12.1. Introduction
12.2. Phase I
12.3. Phase II
12.4. Phase III
12.5. Phase IV
13. Dendritic Cell Cancer Vaccine Market, by Administration Route
13.1. Introduction
13.2. Intraperitoneal
13.3. Intratumoral
13.4. Intravenous
14. Dendritic Cell Cancer Vaccine Market, by Patient Profile
14.1. Introduction
14.2. Adult Patients
14.3. Geriatric Patients
14.4. Pediatric Patients
15. Dendritic Cell Cancer Vaccine Market, by Development Technology
15.1. Introduction
15.2. Peptide-Loaded Dendritic Cells
15.3. RNA-Transfected Dendritic Cells
16. Dendritic Cell Cancer Vaccine Market, by Mechanism of Action
16.1. Introduction
16.2. Direct Tumor Attack
16.3. Immune System Modulation
17. Americas Dendritic Cell Cancer Vaccine Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Dendritic Cell Cancer Vaccine Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Dendritic Cell Cancer Vaccine Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Aduro Biotech
20.3.2. APAC Biotech
20.3.3. Argos Therapeutics
20.3.4. Batavia Biosciences B.V.
20.3.5. Creative Biolabs
20.3.6. Dendreon Pharmaceuticals
20.3.7. GSK PLC
20.3.8. ImmunoCellular Therapeutics
20.3.9. JW CreaGene
20.3.10. Northwest Biotherapeutics
20.3.11. Northwest Biotherapeutics, Inc.
20.3.12. Nouscom
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. DENDRITIC CELL CANCER VACCINE MARKET MULTI-CURRENCY
FIGURE 2. DENDRITIC CELL CANCER VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. DENDRITIC CELL CANCER VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DENDRITIC CELL CANCER VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY FUSION HYBRID DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PROTEIN ANTIGEN DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PURE DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLON CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ALLOGENEIC DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY AUTOLOGOUS DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PEPTIDE-LOADED DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RNA-TRANSFECTED DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DIRECT TUMOR ATTACK, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 96. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 97. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 98. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 99. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 101. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 102. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 103. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 104. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 109. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 110. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 115. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 116. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 163. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 164. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 165. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 166. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 168. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 169. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 170. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 171. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 173. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 176. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 177. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 178. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 179. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 181. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 182. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 184. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 192. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 194. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 202. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 203. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 204. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 205. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 207. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 208. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 209. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 210. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 223. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 228. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 229. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 230. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 231. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 233. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 234. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 235. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 236. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 241. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 242. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 243. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 244. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 246. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 247. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 248. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 249. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 251. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 254. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 255. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 256. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 257. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 259. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 260. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 261. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 262. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 264. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 267. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 268. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 269. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 270. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 277. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 280. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 281. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 282. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 283. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 285. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 286. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 287. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 288. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 289. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 290. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCERS OF THE BLOOD, 2018-2030 (USD MILLION)
TABLE 293. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 294. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 295. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD MILLION)
TABLE 296. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 297. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SOURCE OF DENDRITIC CELLS, 2018-2030 (USD MILLION)
TABLE 298. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CLINICAL TRIAL PHASES, 2018-2030 (USD MILLION)
TABLE 299. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 300. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 301. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY DEVELOPMENT TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 302. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDL

Companies Mentioned

  • Aduro Biotech
  • APAC Biotech
  • Argos Therapeutics
  • Batavia Biosciences B.V.
  • Creative Biolabs
  • Dendreon Pharmaceuticals
  • GSK PLC
  • ImmunoCellular Therapeutics
  • JW CreaGene
  • Northwest Biotherapeutics
  • Northwest Biotherapeutics, Inc.
  • Nouscom

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dendritic Cell Cancer Vaccines - Global Strategic Business Report - Product Image

Dendritic Cell Cancer Vaccines - Global Strategic Business Report

  • Report
  • 142 Pages
  • Global
From
Dendritic Cell Cancer Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Dendritic Cell Cancer Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 92 Pages
  • Global
From
Dendritic Cell Cancer Vaccine Market Report 2025 - Product Image

Dendritic Cell Cancer Vaccine Market Report 2025

  • Report
  • 200 Pages
  • Global
From
2025 Global Forecast for Dendritic Cell Cancer Vaccine Immunotherapy Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Dendritic Cell Cancer Vaccine Immunotherapy Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Cancer Vaccines Market Report by Type,, Technology, Indication, End User, and Region 2025-2033 - Product Image

Cancer Vaccines Market Report by Type,, Technology, Indication, End User, and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From

About the Dendritic Cell Cancer Vaccine Market

The Dendritic Cell Cancer Vaccine is a type of cancer vaccine that uses a patient's own dendritic cells to stimulate an immune response against cancer cells. Dendritic cells are a type of white blood cell that can recognize and respond to foreign substances in the body. The vaccine works by extracting dendritic cells from the patient's blood, loading them with antigens from the patient's cancer cells, and then reintroducing them into the patient's body. This stimulates the patient's immune system to recognize and attack the cancer cells. The Dendritic Cell Cancer Vaccine market is a rapidly growing segment of the cancer vaccine market. It is a promising approach to cancer treatment, as it is personalized to the patient and has the potential to be more effective than traditional cancer treatments. Companies in the Dendritic Cell Cancer Vaccine market include Immunovative Therapies, Inc., ImmunoCellular Therapeutics, Ltd., and OncoImmune, Inc. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.